With the increasing use of mycophenolic acid (MPA) in solid organ transplantation, the need
for more accurate drug dosing has become evident. Personalized immunosuppressive …

Mycophenolate mofetil (MMF) has become the single most used immunosuppressant in
solid-organ transplantation. Despite a well-documented relationship and efficacy (in terms of …

Background & Aims Many recipients of organ transplants develop chronic hepatitis, due to
infection with the hepatitis E virus (HEV). Although chronic HEV infection is generally …

Background. Fixed-dose mycophenolate mofetil (MMF) reduces the incidence of acute
rejection after solid organ transplantation. The Fixed-Dose Concentration Controlled trial …

Background. Lupus nephritis is a life-threatening complication of SLE. Treatment regimes
include steroids and cyclophosphamide, both associated with significant morbidity. Newer …

Once-daily tacrolimus extended-release formulation (Prograf XL, formerly referred to as MR
or MR4) was compared with the twice-a-day tacrolimus formulation (TAC) and cyclosporine …

We studied whether polymorphisms in the UGT1A8, UGT1A9, and UGT2B7 genes, the
enzymes producing the phenolic (MPAG) and acyl (AcMPAG) glucuronides of mycophenolic …

Background. The use of mycophenolate mofetil (MMF) as a primary immunosuppressant
after transplantation is increasing. A number of factors interact to result in variability in blood …

Immunosuppressive drugs in clinical transplantation are necessary to inhibit the immune
response to donor antigens. Although they are effective in controlling acute rejection, they …

An International Conference on the Care of the Kidney Transplant Recipient was convened
in Lisbon, Portugal from February 2–4, 2006 under the auspices of the National Kidney …